In response to the growing global demand for high-quality pharmaceutical intermediates in cardiovascular and heterocyclic drug research, Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. has officially announced the availability of its high-purity intermediate: Ethyl 5-Amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate (CAS No. 256504-39-9). This compound plays a significant role in the synthesis of advanced drug candidates, particularly within the Riociguat-related and soluble guanylate cyclase (sGC) modulator research field.
As chronic cardiovascular diseases continue to rise globally, the need for reliable, scalable, and structurally complex intermediates has become increasingly important. This newly introduced compound supports pharmaceutical innovators in accelerating drug discovery, optimizing synthetic routes, and improving production efficiency.
A Critical Building Block in Heterocyclic Chemistry
Ethyl 5-Amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate is a fluorinated pyrazole derivative characterized by its amino functional group and ethyl ester structure. Its molecular configuration provides excellent reactivity, making it an ideal intermediate for constructing more complex heterocyclic systems used in modern drug design.
The compound is widely recognized for its potential application in the synthesis of Riociguat-related molecules, a class of drugs targeting soluble guanylate cyclase (sGC) pathways. These pathways are critical for regulating vascular tone, improving blood flow, and supporting cardiovascular function.
Its structural features—especially the fluorobenzyl substitution—enhance metabolic stability and improve binding selectivity, making it highly valuable in medicinal chemistry research.
High Purity and Reliable Quality Assurance
Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. ensures that every batch of CAS 256504-39-9 meets strict pharmaceutical-grade quality standards. The product is manufactured under a tightly controlled process, supported by advanced analytical technologies including HPLC, GC, MS, and NMR.
Key quality features include:
- · High purity suitable for pharmaceutical R&D applications
- · Stable chemical structure with consistent batch-to-batch reproducibility
- · Strict impurity control and validated analytical methods
- · Full COA (Certificate of Analysis) support for regulatory compliance
These rigorous quality systems ensure that researchers can rely on consistent performance during multi-step synthesis and drug development workflows.
Advanced R&D and Scalable Manufacturing Capability
One of the core strengths of Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. lies in its integrated R&D and manufacturing platform. The company is equipped with advanced organic synthesis laboratories and pilot-scale production systems, enabling seamless transition from laboratory research to commercial manufacturing.
Production capabilities include:
- · Multi-scale synthesis from gram-level R&D samples to kilogram-scale supply
- · Flexible process development tailored to customer requirements
- · Advanced reaction control technologies for high-efficiency synthesis
- · Strong capability in fluorinated heterocycle chemistry
This scalable production model ensures that global pharmaceutical companies and CDMOs can access reliable supply even during late-stage development and commercialization.
Application in Pharmaceutical Innovation
The CAS 256504-39-9 intermediate is widely used in:
- · Cardiovascular drug research (including sGC modulators such as Riociguat analogs)
- · Heterocyclic compound synthesis
- · Drug discovery and lead optimization studies
- · Advanced medicinal chemistry research
Its amino-pyrazole structure allows it to serve as a versatile scaffold for further functionalization, enabling researchers to design novel therapeutic molecules with improved pharmacological properties.
Synonyms and Chemical Identity
Product Name: Ethyl 5-Amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate
CAS Number: 256504-39-9
Synonyms include:
- · 5-Amino-1-[(2-fluorophenyl)methyl]-1H-pyrazole-3-carboxylic acid ethyl ester
- · 1H-Pyrazole-3-carboxylic acid, 5-amino-1-[(2-fluorophenyl)methyl]-, ethyl ester
These variations reflect its structural classification within fluorinated pyrazole-based intermediates.
Market Outlook and Industry Demand
The global pharmaceutical intermediate market continues to expand, driven by increased investment in cardiovascular therapies, metabolic disease treatments, and targeted drug discovery programs. Fluorinated heterocyclic compounds, in particular, are gaining attention due to their improved stability and pharmacological performance.
As pharmaceutical companies accelerate innovation pipelines, demand for high-purity intermediates like CAS 256504-39-9 is expected to rise steadily.
Why Choose Shanghai Lizhuo Pharmaceutical Technology?
As a trusted supplier in the pharmaceutical intermediate industry, Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. is committed to delivering:Long-term strategic partnerships have been established with multiple high-quality raw material suppliers both domestically and internationally, ensuring a stable supply of key raw materials. A complete warehousing and logistics system enables rapid response and timely delivery. (5) Customization Service: We can provide products of different specifications and purity levels (from 95% to 97%) according to customer needs, supporting customized production from gram-level to ton-level. We also provide impurity reference standards, standard products, and related technical data support. 6.2 Production Capacity
Current Capacity: 50 tons/year of fenelazol intermediates
Planned Capacity: 100 tons/year after Phase II expansion
Packaging Specifications: 1g, 10g, 50g, 100g, 500g, 1kg, 5kg, 10kg, 25kg/drum
Delivery Time: 3-5 working days for standard specifications; 15-30 working days for bulk orders
6.3 Certifications
ISO 9001 Quality Management System Certification
ISO 14001 Environmental Management System Certification
Drug Production License
Application for Certificate of Enzyme Extract (CEP) for Export to EU (underway)
DMF Filing (US FDA)
6.4 Application Areas
Our fenelazol intermediates are widely used in:
Fenelazol API synthesis
Generic drug consistency evaluation research
Impurity research for new drug registration applications
Medicinal chemistry research in research institutes
CRO/CDMO project cooperation
- · Reliable quality backed by strict analytical validation
- · Stable global supply chain and responsive customer service
- · Flexible customization for research and industrial needs
- · Strong expertise in fluorinated and heterocyclic chemistry
- · Compliance with international pharmaceutical standards
Through continuous innovation and strong R&D investment, the company is positioning itself as a long-term partner for global pharmaceutical innovation.
The launch of Ethyl 5-Amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate (CAS 256504-39-9) reflects the ongoing commitment of Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. to advancing high-value pharmaceutical intermediates. With its strong technical capabilities, scalable production systems, and focus on quality, the company is well-positioned to support the next generation of cardiovascular drug development worldwide.
Post time: Jun-23-2026
